The list of national projects SAS

Back to the list of institutes

Institute: Institute for Heart Research

Mechanisms of radiation injury to the heart. Preventive drug treatment.
Mechanizmy poškodenia srdca radiáciou a možnosti medikamentóznej prevencie.
Program: Multilateral - other
Project leader: D.h.c.,Prof., MUDr. Slezák Ján DrSc., FIACS
Duration: 1.1.2014 - 31.12.2017

Multidisciplinary analysis of the combined effects of thyroid hormones and n-3 polyunsaturated fatty acids in rats
Multidisciplinárna analýza kombinovaného vplyvu tyreoidnych hormonov a n-3 polynenasytených mastných kyselin u potkanov
Program: Inter-academic agreement
Project leader: RNDr. Tribulová Narcisa DrSc.
Annotation:Thyroid hormones (TH) play a crucial role in healthy organisms, but profound alterations of their levels can affect metabolic and signaling processes in different tissues. We will use hyper- and hypothyroid rats as “model of a diseased organism” and analyze whether and how n-3 PUFA long term administration will ameliorate TH-induced pathophysiological changes. We will investigate skeletal and cardiac muscle tissue remodeling, changes in serum lipids and in body fat distribution, key enzymes of TH metabolism, oxidative stress in the whole organism and within the cell. We will focus on myosin heavy chain composition, distribution and phosphorylation of connexin-43, cellular calcium handling, membrane anisotropy, mitochondrial functions and related signaling pathways including cell death and antioxidant defense. As n-3 PUFA possess multiple sites of potential action, we believe that our complex research will contribute to a better understanding of molecular mechanisms governing n-3 PUFA actions and to their more effective application in the prevention of pathological symptoms in man.
Duration: 1.1.2015 - 31.12.2017

Realising the therapeutic potential of novel cardioprotective therapies
Realizácia terapeutického potenciálu nových kardioprotektívnych terapií
Program: COST
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.
Duration: 19.10.2017 - 18.10.2021

Investigation of the mechanims involved in antiarrhythmic effects of melatonin
Skúmanie mechanizmov antiarytmických účinkov melatonínu.
Program: Bilateral - other
Project leader: RNDr. Tribulová Narcisa DrSc.
Annotation:Cardiovascular diseases (CVD) are worldwide major cause of morbidity and mortality due to heart failure and incidence of malignant arrhythmias. Main risk factors of CVD are hypertension, diabetes, dyslipidemia, obesity, chronodisruption and stress. Aimed to prevent CVD and life-threatening arrhythmias it seems extremely important to investigate “pleiotropic” effects of endogenous candidate relevant to the CVD, i.e. neurohormone, melatonin. Neuro-humoral circadian rhythms are ‘chronically’ impaired and result in dys-synchrony of cellular cross talk in different tissues of individuals suffering from CVD. Lack of melatonin was repeatedly reported in patients with coronary heart disease. It appears that melatonin may serve as a new biomarker for a CVD risk. Melatonin in addition to its chrono-regulatory role exerts various “pleiotropic” actions: modulation of blood pressure and NO bioavailability, antioxidant, free radicals scavenging and anti-inflammatory effects, sympatholytic and anti-fibrotic potential and epigenetic regulatory function. Of note, previous experimental studies at both institutions showed clear-cut antiarrhythmic effect of melatonin in various pathophysiological conditions. Findings revealed that melatonin up-regulates myocardial connexin-43 (Cx43), protein of intercellular gap junction channels that are important for electrical impulse propagation and synchronization. Besides, melatonin modulates action potential duration suggesting its effect most likely on potassium and/or calcium channels. Nevertheless, there is a need to elucidate more in details the cellular and molecular mechanisms implicated in antiarrhythmic actions of melatonin
Duration: 1.5.2014 - 31.12.2017

Effect of pathological states on cardiac resistance against myocardial ischemia: study of molecular mechanisms and novel approaches to cardioprotection
Vplyv patologických stavov na odolnosť srdca voči ischémii myokardu: štúdium molekulárnych mechanizmov a nových možností kardioprotekcie
Program: Inter-academic agreement
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:Previously, we showed a negative impact of civilization diseases (hypertension, metabolic disorders) on adaptive mechanisms in the heart and its survival under conditions of acute ischemia/reperfusion (I/R). Comorbidities and age- and gender-related changes blunt protective cell signaling of ischemic preconditioning (PC) leading to acceleration of necrotic and apoptotic processes, impaired function of mitochondria and energy production. The project is focused on the study of molecular mechanisms that alter innate cardioprotection in the diseased myocardium and on possibilities to reactivate its adaptive potential. We will explore effects of novel forms of PC, so called „remote“ PC (induced by limb ischemia) that are less technically demanding and can be used in clinical practice, e.g., in elder patients with acute myocardial infarction. Investigation of mechanisms of „remote“ PC will enable its pharmacological simulation, e.g., using pleiotropic (other than primary) effects of PPAR agonists or their combination with PC that can facilitate stimulatory effect on cardiac resistance against I/R.
Duration: 1.1.2015 - 31.12.2017

The total number of projects: 5